Tracers / [11C]UCB-J
[11C]UCB-J
Also written as [11C]UCB-J; [C-11]UCB-J; UCB-J
- Radionuclide
- C-11 t½ 20.36 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 4
What it is
- Compound class
- Pyrrolidinone SV2A ligand (trifluoroborate-derived, 11C-methylated small molecule)
- Target / mechanism
- Targets synaptic vesicle glycoprotein 2A (SV2A) to visualize synaptic density PMID 42154186
- Clinical application
- Imaging synaptic density in patients with epilepsy and other neurologic, neurodegenerative, or psychiatric conditions PMID 42154186
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Synthra RNplus Synthra | custom manifold | HPLC+SPE | 11 ± 1% (nondecay corrected); 35 ± 4% (decay corrected) no | 100 | (R)-trifluoro(4-((2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl)methyl)pyridin-1-ium-3-yl)borate (UCB-J precursor) UCB, Belgium | 32027052 2020 J Labelled Comp Radiopharm Synthra RNPlus synthesizer — The nondecay corrected radiochemical yield was 11 ± 1% (n = 7) and if decay corrected 35 ± 4% (n = 7). |
| In-house / custom built Siemens | — | — | 72 ± 10% yes | — | — | 33238289 2021 Nature our 11C-labeling protocol was independently performed by Siemens Molecular Imaging Biomarker Research in North Wales, PA with a robotic, remote-controlled radiosynthetic setup for the preparation of [11C]UCB-J — yielding 72 ± 10% RCY (dc) and 19 ± 2% RCY (ndc) (n = 4) of the radioligand |
| In-house / custom built in-house | custom manifold | HPLC+SPE | 26.7 ± 5.6% yes | 99.3 ± 0.2% | (R)-3-(difluoroboranyl)-4-((2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-l)methyl)-pyridin-1-ium fluoride PharmaSynth AS, Tartu, Estonia | 42154186 2026 EJNMMI Radiopharm Chem we present an in-house-built device for [11C]UCB-J production from [11C]CH3I and a suitably treated boronated precursor — 56 using new preparative HPLC method protocol 2 (RCY 26.7 ± 5.6%) |
| Synthra MeIplus Synthra | — | HPLC+SPE | 21.1 ± 6.1% yes | 99.4 ± 0.2% | (R)-3-(difluoroboranyl)-4-((2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-l)methyl)-pyridin-1-ium fluoride PharmaSynth AS, Tartu, Estonia | 42154186 2026 EJNMMI Radiopharm Chem [11C]CH3I production using the Synthra MeIplus Research device (Synthra GmbH, Hamburg, Germany) — 94 of these syntheses were performed using protocol 1 as preparative HPLC method (RCY 21.1 ± 6.1%) |
Need this precursor?We can point you to suppliers for [11C]UCB-J, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [11C]UCB-J.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with C-11. Merged stage 17: +4 article(s) from c11-synvest1 (row was a mislabelled duplicate of [11C]UCB-J); combined count 5. Compound class inferred from precursor name (not stated outright) -- PMID 32027052: '(R)-trifluoro(4-((2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl)methyl)pyridin-1-ium-3-yl)borate (UCB-J precursor)'.